Dermatology

Standard of Care and Treatment Pathways

At a Glance

Sweet syndrome is usually treated first with systemic corticosteroids such as prednisone, followed by a gradual taper. Mild localized disease may respond to topical or injected steroids, while recurrent or resistant cases may need other medicines or specialist-directed biologic therapy.

The primary goal of treating Sweet syndrome is to quickly shut down the “neutrophil fire” in your skin. Because this condition is driven by an overactive immune response rather than a germ, the standard of care centers on medications that calm inflammation. For most people, the response to the right treatment is remarkably fast, often bringing relief from pain and fever within just 24 to 72 hours ^[1]^[2]^[3].

First-Line: Systemic Corticosteroids

Systemic corticosteroids (such as prednisone) are the “gold standard” and first-line treatment for Sweet syndrome ^[1]^[4]. They work by rapidly reducing the number and activity of neutrophils in the skin.

The Approach: You will typically start with a higher dose to get the inflammation under control quickly. Once the skin begins to clear and the fever breaks, your doctor will slowly lower the dose over several weeks—a process called tapering ^[5].
The Timing: Complete resolution of the eruption can occur rapidly, though treatment courses are individualized in duration to help prevent a relapse ^[6]^[5].
Important Note: If Sweet syndrome is triggered by a specific medication you are taking, stopping that drug is often a key step. In many “drug-induced” cases, the skin clears quickly once the trigger is removed. However, never stop an essential medication without your prescriber’s guidance ^[7]^[8].

Localized and Second-Line Options

If your case is mild or limited to a specific area, or if you cannot take steroids due to other health issues, your doctor may suggest alternative paths.

Topical and Intralesional Steroids: For localized disease—such as neutrophilic dermatosis of the dorsal hands (lesions confined to the backs of the hands)—doctors may use potent steroid creams or inject steroids directly into the plaques (intralesional) ^[9]^[10]. These are often used as “add-ons” to pills or on their own for very mild cases ^[9].
Second-Line Agents: If steroids are not working or the side effects are too severe, “steroid-sparing” medications are used. The most common include:
- Colchicine: Highly effective at stopping neutrophils from migrating into the skin, but requires monitoring for kidney, liver, and drug-interaction risks ^[11].
- Dapsone: An anti-inflammatory drug frequently used for skin conditions involving neutrophils. It requires a specific blood test (G6PD) and hemolysis monitoring ^[9]^[5].
- Potassium Iodide: An older but effective treatment that often yields a prompt response, though thyroid health must be considered ^[12]^[13].

Advanced and Refractory Care

In rare cases where the disease is severe or returns repeatedly (refractory), specialists may use targeted biologic therapies. These “smart drugs” block specific inflammatory signals, such as IL-1 (using drugs like anakinra) or TNF (using drugs like infliximab) ^[14]^[15]. These are typically specialist-directed options, supported mainly by case reports, for patients who do not respond to standard treatments or who have multiple organs involved ^[14].

Treatment Decision Logic

Severity Level	Typical Treatment Path
Localized (Hands or small area, no fever)	High-potency topical steroid creams or intralesional injections ^[9].
Classic/Systemic (Multiple areas, high fever, pain)	First-line: Oral prednisone (tapered) ^[1].
Steroid-Resistant (No improvement on steroids)	Reassess diagnosis and check for infection, then consider second-line agents like colchicine or dapsone ^[12].
Chronic/Severe (Repeated flares or internal organ involvement)	Evaluation for targeted biologic therapy (e.g., IL-1 inhibitors) ^[14].

A Vital Warning on Surgery

If your skin lesions look severe—blistering, turning dusky, or appearing to die (necrosis)—there is a high risk of being misdiagnosed with a “flesh-eating” bacterial infection like necrotizing fasciitis. These conditions can coexist ^[16].

Never delay or refuse emergency surgical or antimicrobial evaluation. Inform the team of your Sweet syndrome history so specialists can consider necrotizing neutrophilic dermatosis alongside infection. In studies of necrotizing neutrophilic disease, up to 94% of patients were initially misdiagnosed ^[16]^[17]. Unnecessary surgery can cause pathergy, where the trauma of the operation causes the Sweet syndrome to flare aggressively at the surgical site ^[18], but untreated necrotizing fasciitis is a time-critical emergency that is fatal. Steroids help control the sterile inflammation ^[19].

Common questions in this guide

What is the usual first treatment for Sweet syndrome?

The usual first treatment is a systemic corticosteroid such as prednisone, especially when lesions are widespread or accompanied by fever. Doctors often start with a higher dose to control inflammation, then lower it gradually as the skin improves.

How quickly should Sweet syndrome improve after treatment begins?

Pain, fever, and skin inflammation often begin improving within 24 to 72 hours after effective treatment starts. The total treatment length and steroid taper vary because the dose must be reduced carefully and some people relapse.

What options are available if I cannot take prednisone?

For mild or localized Sweet syndrome, potent topical steroid creams or steroid injections into the lesions may be considered. If systemic steroids are unsuitable or not effective, a clinician may consider colchicine, dapsone, or potassium iodide; recurrent or severe disease may need specialist-directed biologic treatment.

Should I stop a medication that may have triggered Sweet syndrome?

If a medication is causing Sweet syndrome, stopping it may help the skin clear, but the decision must be made with the prescribing clinician. Do not stop an essential medicine on your own.

Why do blistering or darkening Sweet syndrome lesions need urgent care?

Blistering, dusky, or necrotic skin can resemble necrotizing fasciitis, a life-threatening infection, and both conditions can occur together. Seek emergency evaluation and tell the medical team about your Sweet syndrome; delaying needed infection treatment or surgery can be dangerous, even though unnecessary surgery may worsen Sweet syndrome through pathergy.

Can Sweet syndrome return while prednisone is being reduced?

Yes, symptoms can return during or after a steroid taper, which is why the schedule is individualized and monitored. Tell your clinician if fever, pain, or new lesions reappear; another treatment or a revised plan may be needed.

What monitoring is needed with colchicine or dapsone?

Colchicine may require attention to kidney and liver risks as well as medication interactions. Dapsone requires G6PD testing and monitoring for hemolysis, or red blood cell breakdown; your clinician will decide which tests are needed.

Get notified when new evidence is published on Sweet syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (19)

1
Sweet syndrome: an update on clinical aspects, pathophysiology, and treatment.
Calabrese L, Satoh TK, Aoki R, et al.
Italian journal of dermatology and venereology 2024; (159(6)):645-662 doi:10.23736/S2784-8671.24.07956-8.
PMID: 39560338
2
Characteristics of Sweet syndrome in patients with or without malignancy.
Jung EH, Park JH, Hwan Kim K, et al.
Annals of hematology 2022; (101(7)):1499-1508 doi:10.1007/s00277-022-04850-7.
PMID: 35482090
3
A rare case of acute generalized exanthematous pustulosis-like Sweet syndrome.
Hu BCE, Xia B, Curnow P, et al.
Skin health and disease 2026; (6(3)):329-331 doi:10.1093/skinhd/vzag029.
PMID: 42222695
4
Sweet Syndrome: A Review and Update.
Villarreal-Villarreal CD, Ocampo-Candiani J, Villarreal-Martínez A
Actas dermo-sifiliograficas 2016; (107(5)):369-78.
PMID: 26826881
5
Sweet's Syndrome: An Evidence-Based Report.
Bhat YJ, Hassan I, Sajad P, et al.
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2015; (25(7)):525-7 doi:07.2015/JCPSP.525527.
PMID: 26208558
6
Allopurinol-induced Sweet's syndrome.
Polimeni G, Cardillo R, Garaffo E, et al.
International journal of immunopathology and pharmacology 2016; (29(2)):329-32 doi:10.1177/0394632015599705.
PMID: 26684631
7
Clinical features, treatment, and outcome of granulocyte colony stimulating factor-induced sweet syndrome.
Wu Z, Sun W, He B, Wang C
Archives of dermatological research 2024; (316(10)):685 doi:10.1007/s00403-024-03414-1.
PMID: 39400723
8
Systematic Review: Sweet Syndrome Associated with Inflammatory Bowel Disease.
Sleiman J, Hitawala AA, Cohen B, et al.
Journal of Crohn's & colitis 2021; (15(11)):1864-1876 doi:10.1093/ecco-jcc/jjab079.
PMID: 33891004
9
Neutrophilic dermatosis of the dorsal hands: A review of 123 cases.
Micallef D, Bonnici M, Pisani D, Boffa MJ
Journal of the American Academy of Dermatology 2023; (88(6)):1338-1344 doi:10.1016/j.jaad.2019.08.070.
PMID: 31499154
10
Diagnosis of Sweet's syndrome in otolaryngology.
Berger DMS, Schaeffers AWMA, van Dijk MR, Kamalski DMA
BMJ case reports 2021; (14(9)) doi:10.1136/bcr-2021-242262.
PMID: 34521737
11
Sweet's syndrome: a retrospective study of 90 cases from a tertiary care center.
Amouri M, Masmoudi A, Ammar M, et al.
International journal of dermatology 2016; (55(9)):1033-9 doi:10.1111/ijd.13232.
PMID: 26967709
12
Acute Onset of Bullous Skin Rash and Acute Kidney Injury after Exposure to Radiocontrast: Sweet's Syndrome.
Abdelnabi M, Cavazos A, Thongpiya J, et al.
European journal of case reports in internal medicine 2023; (10(4)):003781 doi:10.12890/2023_003781.
PMID: 37051479
13
[Classical Sweet syndrome with multiple organ lesions by 18F-FDG PET/CT: A case report].
Chen Z, Qiu Y, Kang L
Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 2025; (57(2)):403-407.
PMID: 40219578
14
Identification of a neutrophil-specific PIK3R1 mutation facilitates targeted treatment in a patient with Sweet syndrome.
Bhattacharya S, Basu S, Sheng E, et al.
The Journal of clinical investigation 2023; (133(1)).
PMID: 36355435
15
Infliximab for the treatment of recalcitrant bullous Sweet syndrome in a 10-year-old girl.
Knöpfel N, Theiler M, Luchsinger I, et al.
Pediatric dermatology 2020; (37(6)):1183-1184 doi:10.1111/pde.14356.
PMID: 32901971
16
Clinical Features of Neutrophilic Dermatosis Variants Resembling Necrotizing Fasciitis.
Sanchez IM, Lowenstein S, Johnson KA, et al.
JAMA dermatology 2019; (155(1)):79-84 doi:10.1001/jamadermatol.2018.3890.
PMID: 30383110
17
Necrotizing Sweet Syndrome of the Hand and Forearm in the Immediate Postoperative Period: Case Report.
Hresko AM, Pickrell BB, Harper CM
Hand (New York, N.Y.) 2024; (19(7)):NP1-NP7 doi:10.1177/15589447231207978.
PMID: 37946497
18
Periorbital Necrotizing Sweet Syndrome: A Case Report and Literature Review.
Bair H, Murdock N, Cheslow L, et al.
Ophthalmic plastic and reconstructive surgery 2026; (42(5)):e226-e231 doi:10.1097/IOP.0000000000003171.
PMID: 41474121
19
A diagnostic challenge-First case of chronic lymphatic leukemia-associated necrotizing sweet syndrome.
Neumann MA, Nieper P, Simon F, et al.
European journal of haematology 2024; (112(4)):650-653 doi:10.1111/ejh.14153.
PMID: 38105522

This page explains Sweet syndrome treatment pathways for informational purposes only and does not constitute medical advice. Your clinician should guide steroid tapering, medication changes, and urgent evaluation of lesions that may represent infection.